Sugi Predict

Sugi Predict / Compounds / SCHEMBL847050

SCHEMBL847050

SCHEMBL847050

CCC(=O)c1ccc(Br)s1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 2/20 0.68
▸ CES2 O00748 1/20 0.59
▸ CES1 P23141 1/20 0.59
▸ DAO P14920 1/20 0.57
▸ NPSR1 Q6W5P4 4/20 0.50
▸ RXFP1 Q9HBX9 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ GAA P10253 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ ESR1 P03372 2/20 0.49
▸ KMT2A Q03164 5/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ POLB P06746 4/20 0.47
▸ HPGD P15428 3/20 0.47
▸ PPARG P37231 2/20 0.47
▸ NCOA2 Q15596 2/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5524032 0.84 GSK3B (0.63) GSK3BCES2CES1DAONPSR1
SCHEMBL15988673 0.83 GSK3B (0.73) GSK3BCES2CES1DAONPSR1
SCHEMBL12541939 0.81 GSK3B (0.59) GSK3BCES2CES1DAONPSR1
SCHEMBL193501 0.81 GSK3B (1.00) GSK3BCES2CES1DAONPSR1
SCHEMBL10844749 0.81 GSK3B (0.70) GSK3BCES2CES1DAONPSR1
SCHEMBL14624168 0.80 GSK3B (0.63) GSK3BCES2CES1DAONPSR1
SCHEMBL28382588 0.80 GSK3B (0.58) GSK3BCES2CES1DAONPSR1
SCHEMBL3998532 0.79 GSK3B (1.00) GSK3BCES2CES1DAONPSR1
SCHEMBL3472612 0.79 GSK3B (0.68) GSK3BCES2CES1DAONPSR1
SCHEMBL2581506 0.79 GSK3B (0.61) GSK3BCES2CES1DAONPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2023-01-12 — — US disclosed
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2023-01-12 — — US disclosed
US-11078170-B2 Cyclic sulfamide compounds and methods of using same ASSEMBLY BIOSCIENCES, INC. (US) 2021-08-03 — — US disclosed
US-11078170-B2 Cyclic sulfamide compounds and methods of using same ASSEMBLY BIOSCIENCES, INC. (US) 2021-08-03 — — US disclosed
EP-3589630-B1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2021-07-07 — — EP disclosed
EP-3589630-B1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2021-07-07 — — EP disclosed
US-20200157070-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2020-05-21 — — US disclosed
US-20200157070-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME ASSEMBLY BIOSCIENCES INC (US) 2020-05-21 — — US disclosed
CN-110621672-A Cyclic sulfonamide compounds and methods of use thereof 组装生物科学股份有限公司 2019-12-27 — — CN disclosed
EP-2822945-B1 AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY COMPOUND HANDLING B V (NL) 2019-06-19 — — EP disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
CN-1774428-A M-phase kinesin inhibitors KYOWA HAKKO KOGYO KK (JP) 2006-05-17 — — CN disclosed
EP-1603883-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2005-12-14 — — EP disclosed
CN-1214022-C Vitamin D analogues GALDERMA RES & DEV (FR) 2005-08-10 — — CN disclosed
CN-1617864-A thiadiazoline derivatives KYOWA HAKKO KOGYO KK (JP) 2005-05-18 — — CN disclosed
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2004-09-30 — — US disclosed
WO-2004069792-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (US) 2004-08-19 — — WO disclosed
CN-1423645-A Vitamin D analogues GALDERMA RES & DEV (FR) 2003-06-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor TRPV1, OPRL1, TRPV2 GSK3B 4397/4885CES2 2159/4885CES1 1113/4885
US-20230012463-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME HCCS, HAVCR2, SLC10A1 GSK3B 1705/4885CES2 431/4885CES1 226/4885
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR TRPV1, OPRL1, TRPV2 GSK3B 4397/4885CES2 2159/4885CES1 1113/4885
US-11078170-B2 Cyclic sulfamide compounds and methods of using same HCCS, HAVCR2, SLC10A1 GSK3B 1705/4885CES2 431/4885CES1 226/4885
US-20200157070-A1 CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME HCCS, HAVCR2, SLC10A1 GSK3B 1705/4885CES2 431/4885CES1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.